Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marco Colleoni

Showing results (121-130 of 264) with videos related to

Pageof 27
Sort By:
Clinical Breast Cancer|May 3, 2015
Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast CancerGiuseppe Cancello, Vincenzo Bagnardi, Claudia Sangalli, et al.
Breast (Edinburgh, Scotland)|July 4, 2012
A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancerSilvia Dellapasqua, Vincenzo Bagnardi, Meredith M Regan, et al.
Cancer|August 27, 2004
Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institutionMattia Intra, Nicole Rotmensz, Giuseppe Viale, et al.
Clinical Breast Cancer|September 13, 2015
Intermittent Letrozole Administration as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer: A Biologic StudyAlessandra Balduzzi, Vincenzo Bagnardi, Maria Teresa Sandri, et al.
Breast (Edinburgh, Scotland)|June 15, 2020
Estimation of historical control rate for a single arm de-escalation study - Application to the POSITIVE trialZhuoxin Sun, Samuel M Niman, Olivia Pagani, et al.
Annals of Surgery|January 21, 2011
Influence of margin status on outcomes in lobular carcinoma: experience of the European Institute of OncologyViviana Galimberti, Patrick Maisonneuve, Nicole Rotmensz, et al.
Breast Cancer Research and Treatment|April 7, 2011
Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer?Viviana Galimberti, Edoardo Botteri, Camelia Chifu, et al.
Anti-Cancer Drugs|August 18, 2021
The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patientsEmilia Montagna, Eleonora Pagan, Giuseppe Cancello, et al.
BMJ (Clinical Research Ed.)|December 22, 2021
Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysisFabio Conforti, Laura Pala, Isabella Sala, et al.
Clinical Breast Cancer|April 24, 2012
Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activityEmilia Montagna, Giuseppe Cancello, Vincenzo Bagnardi, et al.
Pageof 27

Showing results (121-130 of 264) with videos related to

Sort By:
Pageof 27
Clinical Breast Cancer|May 3, 2015
Phase II Study With Epirubicin, Cisplatin, and Infusional Fluorouracil Followed by Weekly Paclitaxel With Metronomic Cyclophosphamide as a Preoperative Treatment of Triple-Negative Breast CancerGiuseppe Cancello, Vincenzo Bagnardi, Claudia Sangalli, et al.
Breast (Edinburgh, Scotland)|July 4, 2012
A risk score based on histopathological features predicts higher risk of distant recurrence in premenopausal patients with lymph node-negative endocrine-responsive breast cancerSilvia Dellapasqua, Vincenzo Bagnardi, Meredith M Regan, et al.
Cancer|August 27, 2004
Clinicopathologic characteristics of 143 patients with synchronous bilateral invasive breast carcinomas treated in a single institutionMattia Intra, Nicole Rotmensz, Giuseppe Viale, et al.
Clinical Breast Cancer|September 13, 2015
Intermittent Letrozole Administration as Adjuvant Endocrine Therapy for Postmenopausal Women With Hormone Receptor-Positive Early Breast Cancer: A Biologic StudyAlessandra Balduzzi, Vincenzo Bagnardi, Maria Teresa Sandri, et al.
Breast (Edinburgh, Scotland)|June 15, 2020
Estimation of historical control rate for a single arm de-escalation study - Application to the POSITIVE trialZhuoxin Sun, Samuel M Niman, Olivia Pagani, et al.
Annals of Surgery|January 21, 2011
Influence of margin status on outcomes in lobular carcinoma: experience of the European Institute of OncologyViviana Galimberti, Patrick Maisonneuve, Nicole Rotmensz, et al.
Breast Cancer Research and Treatment|April 7, 2011
Can we avoid axillary dissection in the micrometastatic sentinel node in breast cancer?Viviana Galimberti, Edoardo Botteri, Camelia Chifu, et al.
Anti-Cancer Drugs|August 18, 2021
The prolonged clinical benefit with metronomic chemotherapy (VEX regimen) in metastatic breast cancer patientsEmilia Montagna, Eleonora Pagan, Giuseppe Cancello, et al.
BMJ (Clinical Research Ed.)|December 22, 2021
Evaluation of pathological complete response as surrogate endpoint in neoadjuvant randomised clinical trials of early stage breast cancer: systematic review and meta-analysisFabio Conforti, Laura Pala, Isabella Sala, et al.
Clinical Breast Cancer|April 24, 2012
Metronomic chemotherapy combined with bevacizumab and erlotinib in patients with metastatic HER2-negative breast cancer: clinical and biological activityEmilia Montagna, Giuseppe Cancello, Vincenzo Bagnardi, et al.
Pageof 27